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Abstract
Background: Preterm newborns are at high risk of developing neurodevelopmental deficits caused by
neuroinflammation leading to perinatal brain injury. Human Wharton’s jelly mesenchymal stem cells (hWJ-MSC) derived
from the umbilical cord have been suggested to reduce neuroinflammation, in part through the release of extracellular
vesicle-like exosomes. Here, we studied whether exosomes derived from hWJ-MSC have anti-inflammatory effects on
microglia-mediated neuroinflammation in perinatal brain injury.
Methods: Using ultracentrifugation, we isolated exosomes from hWJ-MSC culture supernatants. In an in vitro model of
neuroinflammation, we stimulated immortalized BV-2 microglia and primary mixed glial cells with lipopolysaccharide
(LPS) in the presence or absence of exosomes. In vivo, we introduced brain damage in 3-day-old rat pups and treated
them intranasally with hWJ-MSC-derived exosomes.
Results: hWJ-MSC-derived exosomes dampened the LPS-induced expression of inflammation-related genes by BV-2
microglia and primary mixed glial cells. The secretion of pro-inflammatory cytokines by LPS-stimulated primary mixed
glial was inhibited by exosomes as well. Exosomes interfered within the Toll-like receptor 4 signaling of BV-2 microglia,
as they prevented the degradation of the NFκB inhibitor IκBα and the phosphorylation of molecules of the mitogen-
activated protein kinase family in response to LPS stimulation. Finally, intranasally administered exosomes reached the
brain and reduced microglia-mediated neuroinflammation in rats with perinatal brain injury.
Conclusions: Our data suggest that the administration of hWJ-MSC-derived exosomes represents a promising therapy
to prevent and treat perinatal brain injury.
Keywords: Preterm birth, Perinatal brain damage, White matter injury, Neuroinflammation, Hypoxia-ischemia,
Mesenchymal stem cells, Umbilical cord, Extracellular vesicles, Exosomes, Intranasal, Microglia, BV-2
Background
Preterm birth is the leading cause for neonatal morbidity
and mortality in developed countries [1]. Survivors of
preterm birth are at risk of developing neonatal morbid-
ities such as infections, necrotizing enterocolitis, broncho-
pulmonary dysplasia, and brain injury [2, 3].
Perinatal brain injury causes typical neurodevelopment
deficits such as motor impairments, mental and develop-
mental retardation, learning disabilities, and psychiatric
disorders later in life [4–6]. The pathogenesis of peri-
natal brain injury is complex, but is thought to involve
both inflammation and ischemia leading to the forma-
tion of free radicals and subsequent death of neurons
and pre-oligodendrocytes [7]. Additionally, the innate
immune response plays a key role in the pathogenesis of
perinatal brain injury. The main mediators of the innate
immune response to brain injury are microglial cells, the
brain’s resident macrophages. Once activated upon
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injury, microglial cells release a large number of inflam-
matory factors designed to limit infectious processes.
However, this immune defense mechanism causes add-
itional brain injury and contributes substantially to the
subsequent neurodevelopment deficits [8]. Hence, mul-
tiple studies have shown that therapies targeting
microglia-mediated inflammation confer neuroprotec-
tion in several types of brain injuries [9–12], suggesting
that microglia may be a novel therapeutic target for peri-
natal brain injury [13].
Stem cell-based therapies have recently been shown to
be an effective treatment for some of the main morbid-
ities associated with preterm birth [14]. Mesenchymal
stem cells (MSC) have been shown to be promising
therapeutic candidates for preterm birth-associated dis-
eases due to their widely known regenerative and immu-
nomodulatory capacities [15–17].
Human Wharton’s jelly mesenchymal stem cells
(hWJ-MSC) are particularly promising for treating
preterm-related bronchopulmonary dysplasia [18] and
amniotic fluid mesenchymal stem cells for treating
severe necrotizing enterocolitis [19]. With regards to
perinatal brain injury, hWJ-MSC have also been
shown to reduce neuroinflammation and induce
neuroregeneration [14]. Although hWJ-MSC express
neural markers and are able to differentiate into
neuroglia cells in vitro [20–22], their regenerative ef-
fects are thought to be primarily exerted via modula-
tion of the host immune response [23]. Accordingly,
numerous studies have shown that MSC secrete
anti-inflammatory cytokines [12, 24] and release extra-
cellular vesicles [10] such as exosomes [9, 25] that
modulate the immune response.
Exosomes are small membrane vesicles (30–150 nm in
diameter) secreted during the fusion of multivesicular
endosomes with the plasma membrane [26]. They medi-
ate intercellular communication by transferring cell sur-
face receptors, cytokines, lipids, mRNAs, microRNAs,
and long noncoding RNAs from their cell of origin to
their target cell [26]. MSC-derived exosomes hold great
potential for cell-free therapies because they offer safety
and low immunogenicity while still exhibiting the same
immunomodulatory and regenerative capacities of their
mother cells [27]. MSC-derived extracellular vesicles
have been shown to inhibit microglia activation [10],
and exosomes have been used therapeutically to reduce
neuroinflammation after traumatic brain injury [9]. Fur-
thermore, MSC-derived exosomes exhibit particular
promise for treating preterm-associated diseases such as
severe necrotizing enterocolitis [28] and bronchopul-
monary dysplasia [29]. Therefore, our goal was to ex-
plore the anti-inflammatory potential of exosomes
derived from hWJ-MSC for the treatment of perinatal
brain injury.
Methods
Isolation and culture of human Wharton’s jelly-derived
mesenchymal stem cells (hWJ-MSC)
MSC were isolated from the connective tissue of the hu-
man umbilical cord known as Wharton’s jelly. Umbilical
cords from six different donors were collected with writ-
ten informed consent from women with uncomplicated
pregnancies undergoing elective cesarean sections at
term (mean gestational age 38 ± 1.8 weeks, n = 6).
hWJ-MSCs were isolated from the umbilical cords via
enzymatic digestion as previously described [30] and cul-
tured in expansion medium consisting of Dulbecco’s
modified Eagle’s medium (DMEM)/F12 supplemented
with 10% fetal bovine serum (FBS), 2 mmol/l GlutaMAX™,
100 units/ml penicillin, and 100 μg/ml streptomycin
(Thermo Fisher Scientific, Waltham, MA, USA).
Characterization of hWJ-MSC
At passage number 6, hWJ-MSCs were visualized with
bright field microscopy followed by flow cytometric ana-
lysis of cell surface markers. The cells were stained with
fluorescein isothiocyanate-conjugated mouse monoclo-
nal antibodies against human cluster of differentiation
(CD) 105 (AbD Serotec, Oxford, UK), CD90 (Acris Anti-
bodies, San Diego, CA, USA), CD73 (BD Biosciences,
Franklin Lakes, NJ, USA), CD45 (BD Biosciences), CD34
(BD Biosciences), CD19 (Millipore, Billerica, MA, USA)
and CD14 (Millipore), and human leukocyte antigen–
antigen D related (HLA-DR) (BD Biosciences). An
Alexa-Fluor 594-conjugated anti-mouse IgG antibody
(Thermo Fisher Scientific) was used to detect the uncon-
jugated mouse monoclonal antibodies against human
CD73 (BD Biosciences) and CD19 (Millipore). Anti-
bodies were diluted in 1% FBS and phosphate-buffered
saline (PBS) to their working concentration and incu-
bated with hWJ-MSC for 15 min at 4 °C. At least 10′000
events were acquired on a LSR II flow cytometer (BD
Biosciences) and data were analyzed using the FlowJo
software (Tree Star, Inc., Ashland, OR, USA).
Isolation of hWJ-MSC-derived exosomes
Exosomes were isolated from WJ-MSC culture superna-
tants using serial centrifugations according to the proto-
col of Théry et al. [31] and as we previously described
[32]. The pelleted exosomes were resuspended in PBS
and stored at − 20 °C.
Characterization of hWJ-MSC-derived exosomes
Exosomes were characterized according to their size and
surface marker expression using negative-staining elec-
tron microscopy and an Exo-Check Exosome Antibody
Array.
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Negative-staining electron microscopy
The size and shape of hWJ-MSC-derived exosomes were
analyzed with electron microscopy. Aliquots of 5 μl exo-
somes were adsorbed on Formvar® (Formvar resin 15/95,
Ted Pella, Inc., Redding, CA, USA) coated copper grids
for 30 s, washed three times with pure water, and nega-
tively stained with 2% uranyl acetate solution (Electron
Microscopy Sciences, Hatfield, PA, USA) for 30 s. Excess
fluid was removed by gently pushing the copper grids
sideways to filter paper. Samples were visualized with a
transmission electron microscope (CM12, Philips, Eind-
hoven, Netherlands) equipped with a digital camera
(Morada, Soft Imaging System, Münster, Germany) and
image analysis software (iTEM; OSIS, Olympus Soft Im-
aging Solutions, Münster, Germany).
Exo-check exosome antibody array
The exosomal surface marker expression of hWJ-
MSC-derived exosomes was confirmed using the
Exo-Check Exosome Antibody Array (System Biosciences,
Palo Alto, CA, USA). Exosomes were incubated on a
membrane with 12 pre-printed spots of antibodies against
exosomal markers CD63, CD81, ALG-2-interacting pro-
tein X (ALIX), flotillin 1 (FLOT1), intercellular adhesion
molecule 1 (ICAM1), epithelial cell adhesion molecule
(EpCAM), annexin A5 (ANXA5), and tumor susceptibility
gene 101 (TSG101). The GM130 cis-Golgi protein marker
served as a control to exclude cellular contamination. Hu-
man serum exosome proteins served as positive controls.
The array was performed according to the manufacturer’s
instruction.
BV-2 microglia culture
The semi-adherent mouse cell line BV-2 (ATL03001)
was purchased from Banca Biologica e Cell Factory,
Genoa, Italy, and expanded in Roswell Park Memor-
ial Institute (RPMI) 1640 with 10% FBS, 2 mmol/l
GlutaMAX™, 100 units/ml penicillin, and 100 mg/ml
streptomycin. BV-2 cells were detached from culture
plates by mechanical vibrations and flushing with
PBS.
Mixed glial cell culture
Primary mixed glial cells were isolated from cortexes of
2-day-old Wistar rat pups according to the protocol of
Chen et al. [33]. Mixed glial cells were seeded at a dens-
ity of 36′000 cells/cm2cultured in DMEM supplemented
with 10% FBS, 2 mmol/l GlutaMAX™, 1 mmol/l sodium
pyruvate, 100 units/ml penicillin, and 100 μg/ml strepto-
mycin (Thermo Fisher Scientific) on poly-D-lysine
(100 μg/ml, Sigma-Aldrich) coated dishes.
Stimulation of BV-2 and mixed glial cells with
lipopolysaccharide (LPS) and co-culture with
hWJ-MSC-derived exosomes
BV-2 and mixed glial cells were seeded at a density of
18'000 cells/cm2 and 36'000 cells/cm2, respectively, before
being incubated with 100 ng/ml LPS (Sigma-Aldrich) for
0, 15, 30, or 60min for intracellular signaling analysis
(BV-2 cells only), for 6 h for inflammation-related gene ex-
pression and cytokine analysis and for 24 h for cytokine
secretion analysis. hWJ-MSC-derived exosomes (1 μg/ml)
were added simultaneously with LPS. As controls, cells
were cultured either without the addition of LPS and exo-
somes or with 1 μg/ml exosomes only.
Animal model of perinatal brain injury
Perinatal brain injury was introduced in 2-day-old Wis-
tar rat pups using a combination of hypoxic-ischemic
and inflammatory insults outlined in Fig. 1a. For this,
pregnant Wistar rats (Janvier Labs, Le Genest-Saint-Isle,
France) were housed under specific pathogen-free condi-
tions on a 12-h light/dark cycle with ad libitum access to
water and standard laboratory chow. On postnatal day 2,
rat pups were randomly assigned to three experimental
groups (Fig. 1b): Healthy (n = 9), Injury (n = 9), and In-
jury + Exo (n = 8). Healthy animals received a saline in-
jection, were sham operated, kept under normoxic
conditions, and received no exosomes. Injury and Injury
+ Exo animals received an intraperitoneal injection of
0.1 mg/kg LPS in saline (Escherichia coli 0111:B4;
Sigma-Aldrich), followed by the cauterization of the left
common carotid artery 2 h later and exposure to hypoxia
(8% O2/92% N2, 3 l/min,) for 65 min, as previously de-
scribed [14]. Between the LPS injection and the ligation,
Injury + Exo animals received exosomes in PBS (50 mg/
kg) by intranasal administration, whereas Injury animals
received PBS only. An increased permeability of the
nasal mucosa was ensured by a 1 μl drop of hyaluroni-
dase (100 U in PBS, Sigma-Aldrich) into the nostril 30
min before the exosome or PBS administration. For
inflammation-related gene and cytokine expression,
Healthy (n = 5), Injury (n = 6), and Injury + Exo (n = 5)
animals were sacrificed 24 h post insult on postnatal day
3 by decapitation. Brains were collected and stored at
− 80 °C. For immunohistochemistry, Healthy (n = 4), Injury
(n = 3), and Injury + Exo (n = 3) animals were sacrificed
with sodium pentothal and transcardially perfused with
PBS and 4% paraformaldehyde 24 h post insult on post-
natal day 3. Brains were fixed in 4% paraformaldehyde
and embedded in paraffin.
Exosome uptake into BV-2 and mixed glial cells
Confocal microscopy
Exosomes were stained with 2 × 10−6 M PKH26 accord-
ing to the manufacturer’s protocol (Sigma-Aldrich).
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BV-2 and mixed glial cells were seeded at a density of
25,000 cells/cm2 and 50,000 cells/cm2, respectively, in
chamber slides for overnight attachment before they
were co-cultured with PKH26-labeled exosomes for
6 h. Co-cultures were then fixed with 4% paraformal-
dehyde and blocked with 1% bovine serum albumin
(BSA; Sigma-Aldrich) and 0.25% Triton X-100 (Sig-
ma-Aldrich) in PBS for 1 h at room temperature.
Cells were stained overnight with a rabbit primary
antibody against β-tubulin (1:200, ab6046, Abcam,
Cambridge, UK) at 4 °C followed by the detection
with an anti-rabbit IgG Alexa Fluor 488 secondary
antibody (1:200, Thermo Fisher Scientific) at room
temperature for 1 h. Nuclei were counterstained using
4′,6-diamidino-2′-phenylindole-dihydrochloride (DAPI;
Sigma-Aldrich). Confocal images were acquired on a
laser scanning microscope (Carl Zeiss LSM 710) with
a 63x magnification. Images were processed in Imaris
software licensed to the Microscopy Imaging Center
of the University of Bern.
Flow cytometry
Exosomes were stained with 2 × 10−6 M PKH26.
PKH26-labeled exosomes (1 μg/ml) were cultured with
BV-2 (25′000 cells/cm2) and mixed glial cells (50′000
cells/cm2) in 10-cm cell culture dishes for 15 min, 30
min, 3 h, 6 h, or 8 h. After co-culture, cells were har-
vested and fixed with 1% paraformaldehyde. At least
10'000 events were acquired on a LSR II flow cytometer
(BD Biosciences), and data were analyzed using the
FlowJo software (Tree Star, Inc).
RNA and protein isolation
RNA and protein were isolated using the QIAshredder
and the Allprep DNA/RNA/Protein Mini Kit according to
the manufacturer’s protocol (Qiagen, Hilden, Germany).
RNA concentration was measured using a NanoVue Plus™
spectrophotometer (Biochrom, Holliston, MA, USA).
RNA purity was assessed by measuring the 260 nm/280
nm ratio. A ratio between 1.8 and 2.1 was considered as
pure and high-quality RNA. Up to 3 μg RNA was reverse
Fig. 1 Rat model of perinatal brain injury. a Schematic representation of the experimental outline. Perinatal brain injury was induced in postnatal
day 2 (P2) rat pups by i.p. injection of LPS, followed by left common carotid artery cauterization 2 h later and exposure to hypoxia for 65 min.
Hyaluronidase was administered into both nostrils 30 min before i.n. exosome or PBS application and the latter was done immediately before the
cauterization of the left common carotid. b Detailed overview of the three experimental groups. ELISA enzyme-linked immunosorbent assay, Exo
exosomes, i.p. intraperitoneal, i.n. intranasal, n number of animals, P2 postnatal day 2, RT-PCR reverse transcription polymerase chain reaction
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transcribed using the SuperScript III First-Strand Synthe-
sis System (Thermo Fisher Scientific). Total protein con-
centration was determined using the Bicinchoninic Acid
Protein Assay Kit (Sigma-Aldrich).
Gene quantification by real-time polymerase chain
reaction (RT-PCR)
Gene expression in animal brains and cells in culture
was quantified using real-time reverse transcription
polymerase chain reaction (RT-PCR). Gene expression
of C-X-C motif chemokine ligand (Cxcl) 2, Cxcl10, Inter-
leukin (Il) 1b, Il6, and Tnf was quantified by real-time
RT-PCR using the gene expression assays given in
Table 1.
The PCR cycling program was run for 2 min at 50 °C,
then for 10 min at 95 °C, followed by 45 cycles of 15 s at
95 °C and 1min at 60 °C on a QuantStudio™ 7 Flex
Real-Time PCR System (Thermo Fisher Scientific). The
housekeeping gene glyceraldehyde-3-phosphate de-
hydrogenase was used as endogenous control, and pri-
mer and probe sequences were adopted from RT Primer
Database [34]. Data was analyzed using the QuantStu-
dio™ Real-Time PCR software (Thermo Fisher Scientific).
Gene expression was calculated using the 2−ΔΔCt method
relative to untreated BV-2 or mixed glial cells or to total
rat brain RNA (Amsbio, Abingdon, UK).
Evaluation of IL-6, IL-1β, and TNFα via enzyme-linked
immunosorbent assay (ELISA)
IL-1β and TNFα protein levels in brain lysates and su-
pernatants from mixed glial cells were evaluated follow-
ing the manufacturer’s instructions using rat IL-1β and
TNFα DuoSet® ELISA development systems (Bio-Techne,
Minneapolis, MN, USA). IL-6 and TNFα levels in
supernatants from BV-2 cells were evaluated using
mouse IL-6 and TNFα DuoSet® ELISA development
systems (Bio-Techne) after 6 and 24 h of co-culture
with exosomes.
Intracellular signaling evaluation by Western blot analysis
Proteins were separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) on a 4 to 20%
gradient gel (Bio-Rad Laboratories, Inc., Hercules, CA,
USA) and transferred onto nitrocellulose membranes
(Thermo Fisher Scientific). Membranes were blocked with
5% BSA (Sigma-Aldrich) in Tris-buffered saline (TBS).
Proteins were analyzed with rabbit antibodies against nu-
clear factor of kappa light polypeptide gene enhancer in B
cells inhibitor, alpha (IκBα) (product number 9242), p44/
42 MAPK (Erk1/2) (9102), phospho-p44/p42 MAPK
(Erk1/2) (Thr202/Tyr204) (9101), SAPK/JNK (9252),
phospho-SAPK/JNK (Thr183/Tyr185) (4668), p38 MAPK
(8690), phospho-p38 MAPK (Thr180/Tyr182) (9215) (all
1:1000, Cell Signaling Technology, Boston, MA, USA),
and β-tubulin (ab6046, 1:1000, Abcam) in 5% BSA in
TBS-Tween 20 (Sigma-Aldrich) overnight at 4 °C. Horse-
radish peroxidase-coupled donkey anti-rabbit (1:1000, GE
Healthcare Life Science, Piscataway, NJ, USA) antibody
was used as a secondary antibody and incubated with the
membranes for 1 h at room temperature. Binding was de-
tected using the chemiluminescent Amersham ECL Prime
Western Blotting Detection Reagent (GE Healthcare Life
Sciences) on a Chemidoc XRS+ system (Bio-Rad). Pixel
summation of individual bands was performed with Ima-
geJ Software (NIH, Bethesda, MD, USA). The ratio be-
tween IκBα and β-tubulin as well as the ratios between
the phosphorylated and the total ERK1/2, JNK, and p38
were calculated for each time point.
Immunohistochemistry
To detect inflammation-related microglia accumulation,
coronal brain paraffin sections (6 μm) were incubated with
anti-ionized calcium-binding adaptor protein 1 (Iba1;
1:100; ab5076 Abcam) and anti-CD68 (1:100; ab31630
Abcam) antibodies overnight at 4 °C. Anti-Iba1 antibody
was followed by a peroxidase-labeled secondary antibody
(1:200; Dako, Glostrup, Denmark), and binding was visual-
ized with diaminobenzamidine and the EnVision+
System-HRP (Dako). Anti-CD68 antibody was followed by
an Alexa Fluor 488-labeled secondary antibody (1:200;
Thermo Fisher Scientific). Sections were counterstained
with hematoxylin (Iba1) and DAPI (CD68). Images were
acquired with fluorescent (CD68) and bright field (Iba1)
microscopy on a Leica DM6000 B microscope (Leica
Microsystems, Wetzlar, Germany). Iba1- and CD68-posi-
tive areas within the corpus callosum were used as a
measure for microglia accumulation in the white matter.
Table 1 Taqman gene expression assay (Thermo Fisher Scientific) IDs
Gene Description Assay ID Mus musculus Assay ID Rattus norvegicus
Cxcl2 C-X-C motif chemokine ligand 2 – Rn00586403_m1
Cxcl10 C-X-C motif chemokine ligand 10 – Rn01413889_g1
Il1b Interleukin 1 beta Mm00434228_m1 Rn00580432_m1
Il6 Interleukin 6 Mm00446190_m1 Rn01410330_m1
Il18 Interleukin 18 – Rn01422083_m1
Tnf Tumor necrosis factor Mm00443258_m1 Rn01525860_g1
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Percentages of Iba1- and CD68-positive areas were quan-
tified using ImageJ (NIH, Bethesda, MD, USA).
Statistical analysis
We used one-way analysis of variance (ANOVA) to
compare gene and cytokine expression and microgliosis
between Healthy, Injury, and Injury + Exo animals. To
investigate the impact of exosome treatment on gene
and cytokine expression in the setting of unstimulated
and LPS-stimulated cells, we used two-way ANOVA
with LPS and exosome treatment as factors and also in-
cluded an interaction term. One-way ANOVA was used
to analyze the impact of exosome treatment on intracel-
lular signaling. The Shapiro-Wilk test was used to test
for normality of distributions in all continuous variables.
Since all continuous variables were normally distributed,
we applied the parametric methods as described. All re-
ported p values were Bonferroni-adjusted for multiple
comparison, meaning that the family-wise significance
was set to 0.05. Continuous variables were expressed as
mean with 95% confidence interval (CI). Differences be-
tween groups were considered significant if multiplicity-
adjusted p values were less than 0.05. Statistical analysis
was done using Prism (version 7.0, GraphPad Software,
La Jolla, CA, USA).
Results
Characterization of hWJ-MSC and their exosomes
According to the minimal criteria for defining MSC by
the International Society of Cellular Therapy [35], MSCs
have to adhere to plastic, express classical cell surface
markers, and exhibit multipotent differentiation capacity.
We confirmed that the isolated hWJ-MSCs meet these
criteria. Our hWJ-MSCs were plastic adherent and
showed a fibroblast-like morphology (Fig. 2a). They were
also highly positive for mesenchymal stem cell markers
Fig. 2 Characterization of human Wharton’s jelly mesenchymal stem cells (hWJ-MSC) and hWJ-MSC-derived exosomes. a Representative bright
field microscopy image of hWJ-MSC. b Representative flow cytometry histograms of hWJ-MSC at passage 6. c Representative electron microscopy
image of hWJ-MSC-derived exosomes (d) revealing a median diameter of 43 nm. e Representative Exo-Check antibody array of isolated exosomes
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CD105, CD73, and CD90 and negative for cell differenti-
ation markers CD45, CD34, CD14, CD19, and immuno-
genic marker HLA-DR (Fig. 2b). The differentiation
capacity of our hWJ-MSCs into osteoblasts, chondro-
blasts, and adipocytes was already confirmed in our pre-
vious study [20].
Exosomes are defined as small membrane vesicles with
a circular shape and a diameter of 40 to 100 nm [36].
We confirmed that the isolated exosomes are within this
size range as electron microscopy revealed circular
shapes (Fig. 2c) with a median diameter of 42.93 (mini-
mum, 16.34 nm; maximum, 87.18 nm, Fig. 2d). Further-
more, exosomes should express transmembrane or
lipid-bound proteins and endosomal proteins but should
not express intracellular proteins associated with com-
partments other than plasma membrane or endosome
[37]. We confirmed that the isolated exosomes expressed
membrane proteins such as CD63, CD81, Flotilin 1,
EpCam, and ICAM as well as endosome proteins such
as TSG101, ANXA5, and ALIX but did not express cel-
lular contamination marker cis-Golgi matrix-associated
protein GM130 (Fig. 2e).
Internalized exosomes reduce LPS-induced production of
pro-inflammatory molecules in BV-2 cells
The interaction between hWJ-MSC-derived exosomes
and their target cells is essential for the mediation of a
therapeutic effect [26]. Therefore, we first tested whether
hWJ-MSC-derived exosomes are taken up by murine
BV-2 cells. For this, PKH26-labeled exosomes were
co-cultured with BV-2 cells for 6 h. The labeled exosomes
co-localized with BV-2 cells, were mainly located in the
perinuclear region, and were only found within the BV-2
cell margins thus indicating their complete internalization
(Fig. 3a). The internalization of PKH26-labeled exosomes
by BV-2 cells was quantified using flow cytometry. For
this, the cells were co-incubated with exosomes for 15
min, 30min, 3 h, 6 h, or 8 h. Within 30min, around 73%
of BV-2 cells were PKH26-positive. After 3 h, all BV2-cells
became positive for PKH26 (Fig. 3b).
The production and release of pro-inflammatory cyto-
kines are essential in microglia-mediated inflammation.
Therefore, we evaluated the capacity of hWJ-MSC-derived
exosomes to prevent microglia-mediated inflammation by
measuring their effect on the transcription and release of
the most relevant pro-inflammatory molecules by BV-2
cells.
LPS stimulation for 6 h led to the increased transcrip-
tion of genes encoding Tnf, Il6, and Il-1β in BV-2 cells
(Fig. 3c). After 6 h of BV-2 stimulation with LPS, Tnf tran-
scripts were upregulated 3.39 ± 0.88-fold (p < 0.0001). Exo-
somes suppressed Tnf transcript upregulation by 17.7%
(2.79 ± 0.59-fold; p = 0.0053) compared to LPS-stimulated
cells. Similarly, exosomes suppressed Il6 transcript
upregulation by 29.9% (55.71 ± 21.66-fold; p = 0.0267)
relative to LPS-stimulated cells (75.18 ± 33.46-fold; p <
0.0001). Exosomes did not reduce the upregulation of Il1b
(9.16 ± 5.08-fold; p > 0.9999) compared to LPS-stimulated
cells (9.84 ± 5.09-fold; p = 0.0022). The co-culture of un-
stimulated BV-2 cells with exosomes did not induce any
significant up- or downregulations in the expression of
the assessed genes (Fig. 3c). There was a significant inter-
action between exposure and treatment in the sense that
exosome treatment had only an impact on LPS-exposed
cells.
LPS stimulation induced the secretion of pro-
inflammatory cytokines TNFα and IL-6 in BV-2 cells.
After 6 h of LPS stimulation, BV-2 cells secreted signifi-
cantly more TNFα (1785 ± 99 pg/ml) than unstimulated
cells (257 ± 61 pg/ml; p < 0.0001) (Fig. 3d). Exosomes
dampened the LPS-induced TNFα secretion by 13.4%
(1546 ± 126 pg/ml; p = 0.0005) compared to LPS-stimulated
cells. After 24 h of LPS stimulation, BV-2 cells secreted sig-
nificantly more TNFα (1689 ± 151 pg/ml) than unstimu-
lated cells (586 ± 192 pg/ml; p < 0.0001). Exosomes did not
decrease the LPS-induced TNFα level (1485 ± 124 pg/ml;
p = 0.2561) compared to LPS-stimulated cells. After 6 and
24 h of LPS stimulation, BV-2 cells also secreted signifi-
cantly more IL-6 (272 ± 96 pg/ml and 405 ± 232 pg/ml)
than unstimulated cells (4 ± 1 pg/ml; p < 0.0001 and
4 ± 1 pg/ml; p = 0.0003) (Fig. 3d). Exosomes dampened the
LPS-induced increase in IL-6 secretion significantly by
16% after 6 h (228 ± 83 pg/ml; p = 0.0483). After 24 h,
exosomes had no effect on LPS-induced IL-6 secretion
(308 ± 158 pg/ml; p > 0.9999). The co-culture of unstimu-
lated BV-2 cells with exosomes did not induce any signifi-
cant in- or decrease in cytokine secretion (Fig. 3d). As
reported for the gene expression levels, the interaction be-
tween LPS stimulation and exosome treatment was sig-
nificant; exosome treatment influenced cytokine secretion
in LPS-stimulated cells only. Levels of Il-1β secretion were
also measured in the cell culture supernatants, but they
were below the detectable range of the used ELISA kit.
Exosomes inhibit LPS-induced TLR4/CD14 signaling in BV-2
LPS stimulates microglia via the membrane receptor
complex TLR4/CD14, inducing the production of
pro-inflammatory cytokines such as TNFα, IL-6, and
interferon gamma (IFNγ). The TLR4/CD14 signaling
pathway is mediated by regulators of NFκB such as IκBα,
as well as by regulators of activation protein 1 (AP-1)
such as the mitogen-activated protein kinase (MAPK)
family members ERK1/2, p38, and JNK. We assessed
whether hWJ-MSC-derived exosomes interfere with the
degradation of IκBα and the phosphorylation of the
MAPK family to prevent NFκB- and AP-1-dependent
transcription of pro-inflammatory cytokines. The deg-
radation of IκBα was significantly prevented after 30 min
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of LPS stimulation in BV-2 cells co-cultured with exo-
somes compared to LPS-stimulated BV-2 cells cultured
without exosomes (p < 0.01, Fig. 4a). Also, the exosomes
significantly decreased the phosphorylation of ERK1/2
(p < 0.01) after 15 min and of ERK1/2 (p < 0.0001), JNK
(p < 0.01), and p38 (p < 0.0001) after 30 min of LPS
stimulation compared to the LPS-stimulated BV-2 cells
in absence of exosomes (Fig. 4b–d). After 60 min, no dif-
ference in IκBα expression and ERK1/2, p38, and JNK
phosphorylation between LPS-stimulated BV-2 cells cul-
tured in the presence and absence of exosomes and un-
stimulated cells could be observed (Fig. 4).
Internalized exosomes reduce LPS-induced production of
pro-inflammatory molecules in primary mixed glial cells
Even though BV-2 cells are widely accepted as an appro-
priate cell line model for murine microglia, they do not
reflect all properties of primary microglia. Thus, we
aimed to confirm the immunomodulatory effects of
hWJ-MSC-derived exosomes found in BV-2 cells using
primary mixed glial cells consisting of microglia and
astrocytes.
Again, we tested whether the exosomes are taken up
by rat mixed glial cells. After 6 h of co-culture, the
PKH26-labeled exosomes co-localized with mixed glial
Fig. 3 Anti-inflammatory effects of internalized human Wharton’s jelly mesenchymal stem cell-derived exosomes on BV-2 cells. a Representative
confocal image after the co-culture of exosomes with BV-2 cells for 6 h. Exosomes were labeled with the fluorescent membrane dye PKH26 (red).
BV-2 cells were stained with β-tubulin (green), and their nuclei were counterstained with 4′,6-diamidino-2′-phenylindole-dihydrochloride (DAPI)
(blue). b PKH26-labeled exosomes (1 μg/ml) were co-cultured with BV-2 cells for 15 min, 30 min, 3 h, 6 h, or 8 h and analyzed by flow cytometry.
c Quantification of Tnf, Il6, and Il1b mRNA expressed by BV-2 cells either left untreated or stimulated with LPS and/or co-incubated with 1 μg/ml
exosomes for 6 h. d Quantification of TNFα and IL-6 secretion by BV-2 cells either left untreated or stimulated with LPS and/or co-incubated with
1 μg/ml exosomes for 6 or 24 h. Error bars illustrate mean ± 95% CI of n = 3 (b), n = 10 (c), and n = 7 (d) biological replicates. *p < 0.05 **p < 0.01,
***p < 0.001, ****p < 0.0001, n.s. non-significant, CI confidence interval, Exo exosomes, Il1b/Il-1β interleukin 1 beta, Il6/IL-6 interleukin-6, LPS
lipopolysaccharide, Tnf/TNFα tumor necrosis factor α
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cells, were mainly located in the perinuclear region, and
were only found within the mixed glial cell margins, thus
indicating their complete internalization (Fig. 5a). As
previously done for BV-2 cells, we quantified exosome
internalization by mixed glial cells using flow cytometry.
For this, mixed glial cells were co-incubated with
PKH26-labeled exosomes. After 3 h of co-culture, 30%
of mixed glial cells became positive for PKH26. Upon
8 h of co-incubation, nearly 60% of cells were PKH26
positive (Fig. 5b).
Comparable to what we found in BV-2 cells, the tran-
scription of the genes encoding TNFα, IL-6, and IL-1β
was upregulated after LPS stimulation in mixed glial cells.
Furthermore, exosomes dampened the transcription of
Tnf, but not the transcription of Il6 and Il1b in mixed glial
cells stimulated with LPS (Fig. 5c). Specifically, after 6 h of
LPS stimulation of mixed glial cells, Tnf transcripts were
upregulated 88.40 ± 39.62-fold (p < 0.0001). Exosomes
suppressed Tnf transcripts by 20.1% (70.68 ± 35.55-fold; p
= 0.0168) compared to LPS-stimulated cells. Exosomes
did not influence the LPS-stimulated upregulation of
Il6 and Il1b transcription (80.04 ± 29.62-fold; p > 0.999
and 386.88 ± 192.39-fold; p > 0.999) compared to
LPS-stimulated mixed glial cells (94.73 ± 26.58-fold; p
< 0.0001 and 490.04 ± 185.22-fold; p < 0.0001). The
co-culture of unstimulated mixed glial cells with exo-
somes did not induce any significant up- or downre-
gulations in the expression of the assessed genes
(Fig. 5c). The interaction between exposure and treat-
ment was significant, and exosome treatment had
only an impact on LPS-exposed cells.
At the protein level, similar to our findings in BV-2 cells,
stimulation with LPS led to a statistically significant in-
crease in TNFα and IL-1β secretion in mixed glial cells.
Additionally, exosomes significantly dampened the secre-
tion of both TNFα and IL-1β by mixed glial cells after LPS
stimulation (Fig. 5d). After 6 h of LPS stimulation, mixed
glial cells secreted significantly more TNFα (295.90 ±
22.86 pg/ml) than unstimulated cells (50.83 ± 4.67 pg/ml;
p < 0.0001). Exosomes dampened the LPS-induced TNFα
Fig. 4 The anti-inflammatory effects of human Wharton’s jelly mesenchymal stem cell-derived exosomes are mediated via the Toll-like receptor
4 pathway. BV-2 cells were either left untreated or stimulated with LPS and/or co-incubated with exosomes for 15, 30 or 60 min. Western blot
analysis of the expression of a NFκB inhibitor IκBα and the phosphorylation of MAPK family molecules b ERK, c JNK, and d p38. Error bars
illustrate mean ± 95% CI of n = 4 biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 CI confidence interval, Exo exosome, p
phosphorylation, IκBα nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha MAPK mitogen-activated protein kinase,
LPS lipopolysaccharide, NFκB nuclear factor kappa-light-chain-enhancer of activated B cells
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secretion by 20.3% (235.96 ± 57.61 pg/ml; p = 0.0137)
relative to LPS-stimulated cells. After 24 h of LPS
stimulation, mixed glial cells still secreted significantly
more TNFα (440.83 ± 68.96 pg/ml) than unstimulated
cells (60.99 ± 9.60 pg/ml; p < 0.0001). Exosomes did not
affect the TNFα secretion in stimulated cells (379.92 ±
43.64 pg/ml; p > 0.999). After 6 h of LPS stimulation,
mixed glial cells also secreted significantly more IL-1β
(174.39 ± 19.53 pg/ml) than unstimulated cells (< 62.5
pg/ml [values below detectable range]; p < 0.0001). In
stimulated mixed glia cells, exosomes significantly re-
duced the IL-1β secretion by 26.7% (127.79 ± 17.81 pg/ml;
p < 0.0001) relative to LPS-stimulated cells. After 24 h
of LPS stimulation, mixed glial cells still secreted
significantly more IL-1β (146.09 ± 24.78 pg/ml) than
unstimulated cells (1.08 ± 0.62 pg/ml; p < 0.0001) and
exosomes significantly dampened the upregulation of
IL-1β secretion by 28.5% (104.47 ± 35.93 pg/ml; p =
0.0153) compared to LPS-stimulated cells. The
co-culture of unstimulated mixed glial cells with exo-
somes did not induce any significant change in cytokine
secretion. There was a significant interaction between
exposure and treatment since exosome treatment had
an impact on LPS-exposed cells only.
Fig. 5 Anti-inflammatory effects of internalized human Wharton’s jelly mesenchymal stem cell-derived exosomes on primary mixed glial cells.
a Representative confocal image after the co-culture of exosomes with primary mixed glial cells for 6 h. Exosomes were labeled with the
fluorescent membrane dye PKH26 (red). Primary mixed glial cells were stained with β-tubulin (green) and their nuclei were counterstained with
4′,6-diamidino-2′-phenylindole-dihydrochloride (DAPI) (blue). b PKH26-labeled exosomes (1 μg/ml) were co-cultured with mixed glial cells for 15min,
30 min, 3 h, 6 h, or 8 h and analyzed by flow cytometry. c Quantification of Tnf, Il6, and Il1b mRNA expressed by mixed glial cells either left
untreated or stimulated with LPS and/or co-incubated with exosomes for 6 h. d Quantification of TNFα and IL-1β secretion by mixed glial cells
either left untreated or stimulated with LPS and/or co-incubated with exosomes for 6 or 24 h. Error bars illustrate mean ± 95% CI of n = 3 (b),
n = 9 (c), and n = 6 (d) biological replicates. *p < 0.05, ****p < 0.0001, n.s. non-significant, CI confidence interval, Exo exosomes, Il1b/Il-1β
interleukin 1 beta, Il6/IL-6 interleukin-6, LPS lipopolysaccharide, Tnf/TNFα tumor necrosis factor α
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hWJ-MSC-derived exosomes inhibit the production of
pro-inflammatory molecules and prevent microgliosis in
rats with perinatal brain injury
Next, we evaluated the anti-inflammatory potential of
intranasally administered hWJ-MSC-derived exosomes
in a rat model of perinatal brain injury. The expres-
sion of genes encoding pro-inflammatory markers
(Cxcl2, p = 0.0177; Cxcl10, p = 0.0010; Il1b, p < 0.0001;
Il18, p = 0.0066; Tnf, p < 0.0001) was significantly in-
creased in the brain 24 h after brain injury. Intranasal
administration of exosomes significantly prevented this
upregulation for most pro-inflammatory markers analyzed
(Cxcl10, p = 0.0012; Il1b, p = 0.0034; Il6, p = 0.0099; Tnf,
p = 0.0004) relative to untreated animals (Fig. 6a). The
protein expression of pro-inflammatory cytokines such as
IL-1β and TNFα in brain parenchyma was strongly upreg-
ulated 24 h after brain injury. Intranasal administration of
exosomes significantly prevented the increased expression
of these cytokines. More specifically, LPS stimulation in-
duced a 20-fold expression of TNFα 24 h after brain injury
(976.82 ± 102.32 pg/ml) relative to healthy animals (46.23
± 15.37 pg/ml; p < 0.0001). Exosomes successfully de-
creased the injury-related TNFα expression by 43.6%
(550.86 ± 162.54 pg/ml; p < 0.0001). IL-1β secretion was
three-fold higher 24 h after brain injury (152.32 ±
16.04 pg/ml) than in healthy animals (54.62 ± 12.80 pg/ml;
p < 0.0001). Exosomes decreased the IL-1β expression in
injured brains by 42.0% (88.40 ± 9.93 pg/ml; p < 0.0001)
(Fig. 6b).
A key hallmark of the brain’s response to insults is
the activation and proliferation of microglia, a reac-
tion called microgliosis. Thus, we analyzed the poten-
tial of hWJ-MSC-derived exosomes to prevent
microgliosis in the corpus callosum, a white matter
region known to be especially vulnerable to perinatal
brain injury [38, 39]. In healthy animals, very few
microglia are present within the corpus callosum as
only 0.47 ± 0.43% and 0.11 ± 0.09% of the total area of
the corpus callosum stained positive for microglia
markers Iba1 (Fig. 7a) and CD68 (Fig. 7b), respect-
ively. One day after injury, the area of the corpus cal-
losum occupied by Iba1+ cells was increased by 60.7%
(1.20 ± 0.81% of the total area; p = 0.0256). Upon
treatment of injured animals with exosomes, the re-
gion of Iba1+ cells decreased by 75% and reached
baseline values (0.30 ± 0.29% of total area; p = 0.0126).
Similarly, the area occupied by CD68+ cells increased
in the first 24 h after perinatal brain injury (0.35 ±
0.12% of total area; p = 0.0009). Exosome treatment
reduced the area occupied by CD68+ cells in injured
brains by 37% (0.22 ± 0.07% of total area; p = 0.0379).
Following perinatal brain injury, no microgliosis could
be detected in areas of the cortex, thalamus, and
hippocampus (see Additional file 1: Figure S1).
Discussion
Our study revealed that hWJ-MSC-derived exosomes
have anti-inflammatory effects in perinatal brain injury.
In vitro, we demonstrated that the exosomes are inter-
nalized by microglia cells and reduce the release of
pro-inflammatory cytokines by microglial cells in re-
sponse to LPS stimulation. In vivo, we showed that in-
tranasal administration of hWJ-MSC-derived exosomes
is an effective treatment to reduce neuroinflammation.
The uptake of hWJ-MSC-derived exosomes into their
target cells is an essential prerequisite for their therapeutic
action [26]. In vitro, we showed that hWJ-MSC-derived
exosomes are very efficiently internalized by BV-2 micro-
glia and to a slightly less efficient extent into primary
mixed glial cells. We propose that this difference in uptake
efficiency is due to the different compositions of these two
cell types. While the immortalized BV-2 cells consist
purely of microglia cells, the primary mixed glial cells con-
sist of a mixture of astrocytes and microglia cells. Astro-
cytes have been described as much less efficient as
microglia in clearing debris [40] and specifically in intern-
alizing exosomes [41, 42]. Hence, it is likely that most of
the mixed glial cells that internalized exosomes in our ex-
periment were microglia cells, although this hypothesis re-
mains to be confirmed by further experiments. Within the
brain, microglia cells have been previously described to be
the primary cell type to internalize exosomes after their
intranasal administration in mice [43]. Whether this also
holds true in rats after perinatal brain injury remains to be
tested in future experiments.
Microglia play a pivotal role in the pathophysiology of
perinatal brain injury. Microglial cells exhibit dualistic
functions and can be categorized into a pro-inflammatory
M1 and an anti-inflammatory, regenerative M2 phenotype
[44]. In perinatal brain injury, microglia initially respond
to stimuli such as hypoxia-ischemia or infection with the
production of pro-inflammatory cytokines that eventually
exacerbate brain injury. After the initial pro-inflammatory
phase, microglia eventually switch their phenotype and
start to produce anti-inflammatory molecules favoring tis-
sue repair and neuroregeneration [13]. A complete abro-
gation of microglia function could therefore have
detrimental effects in perinatal brain injury. This dual
functionality of microglia makes immunomodulation the
most promising approach for optimizing the response of
microglial cells during neuroinflammation. Here, we
showed that hWJ-MSC-derived exosomes modulate the
microglial response by interfering with the TLR4/CD14
signaling pathway. Given that exosomes are well known
for their capacity to deliver micro RNAs (miRNAs) [26,
36], we hypothesize that exosomal miRNAs are respon-
sible for the observed immunomodulation. We have previ-
ously described the miRNA content of hWJ-MSC-derived
exosomes [32]. Several exosomal miRNAs have been
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described to be negative regulators of inflammatory gene
expression, such as miR-146a/b, which negatively regulate
the production of pro-inflammatory cytokines via TLR4/
CD14 signaling [45]. Further analysis of MSC-derived exo-
somes is required to better understand how these miRNAs
may convey anti-inflammatory and immunomodulatory
signals to microglia.
Specific interference with TLR4/CD14 signaling explains
why hWJ-MSC-derived exosomes, at least in vitro, are only
effective in dampening certain pro-inflammatory cytokines
such as IL-6 and TNFα and not others such as Il-1β and
IL-18. While IL-6 and TNFα are direct target genes of the
TLR4/CD14 pathway, IL-18 and IL-1β are targets of the
inflammasome cascade [46]. hWJ-MSC-derived exosomes
seem to be effective at interfering with TLR4/CD14 signal-
ing but not at interfering with the inflammasome cascade
in vitro. This finding stands in contrast to the effects of
hWJ-MSC-derived exosomes in our animal model, where
they seem to be able to inhibit IL-1β (but not IL-18), indi-
cating that hWJ-MSC-derived exosomes at least partially
interfere with the inflammasome cascade in vivo. The spe-
cific effects of hWJ-MSC-derived exosomes on the inflam-
masome cascade and on further pathways in animal
models are to be confirmed.
Fig. 6 Anti-inflammatory effects of human Wharton’s jelly mesenchymal stem cell-derived exosomes in perinatal brain injury. a Quantification of
Tnf, Il6, Il1b, Cxcl10, Il18, and Cxcl2 mRNA expressed in the brain of healthy rats and of rats 24 h after injury with and without exosome treatment.
b Quantification of TNFα and IL-1β expression in the brain parenchyma of healthy rats and of rats 24 h after brain injury with and without exosome
treatment. Error bars illustrate mean ± 95% CI of at least four different animals. *p < 0.05, **p < 0.01 ***p < 0.001, ****p < 0.0001, n.s. non-significant, CI
confidence interval, Cxcl2 C-X-C motif chemokine ligand 2, Cxcl10 C-X-C motif chemokine ligand 10, Exo exosomes, Il1b/Il-1β interleukin 1 beta, Il18
interleukin 18, Il6 interleukin-6, Tnf/TNFα tumor necrosis factor alpha
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Furthermore, hWJ-MSC-derived exosomes may reduce
neuroinflammation in vivo in part through peripheral
immunomodulation. After intranasal administration,
some exosomes end up in peripheral organs such as the
spleen. Recently, MSC-derived exosomes have been
shown to modulate peripheral immune responses [47]
which prevented subsequent immune cell invasion
into the brain and thus reduced brain injury [48]. We
suggest that hWJ-MSC-derived exosomes not only
have direct immunomodulatory effects on microglia
in the central nervous system, but also have add-
itional immunomodulatory effects in the periphery.
These additional immunomodulatory effects outside
of the brain could explain why we observed substan-
tially higher immunomodulatory effects in our animal
model than in the microglial cell cultures. This possi-
bility highlights the importance of further research
into the immunomodulatory effects of MSC-derived
exosomes in the periphery.
Microglia-mediated inflammation in our animal
model of preterm brain injury seems to occur pre-
dominantly in the corpus callosum, the main white
matter structure in the brain. This is in accordance
with studies showing that cerebral white matter re-
gions are especially injury-prone in infants born
prematurely [38, 39]. The selective vulnerability to
white matter injury is closely related to the fetal brain
development. During 23 to 32 weeks of gestation,
oligodendrocyte progenitor cells develop according to
a well-defined sequence of maturational events.
Fig. 7 Prevention of microgliosis by human Wharton’s jelly mesenchymal stem cell-derived exosomes in perinatal brain injury. a Representative
chromogenic immunohistochemistry images and quantification of Iba1+ cells in the corpus callosum of healthy rats and of rats 24 h post brain
injury with and without exosome treatment. b Representative fluorescent immunohistochemistry images and quantification of CD68+ cells in the
corpus callosum of healthy rats and of rats 24 h after brain injury with and without exosome treatment. Bottom row images are higher magnifications
(40x) of the top row images (10x). Error bars illustrate mean ± 95% CI of at least three different animals. *p < 0.05, ***p < 0.001, CC corpus callosum, CI
confidence interval, CD68 cluster of differentiation 68, DAPI 4′,6-diamidino-2′-phenylindole-dihydrochloride, Exo exosomes, Iba1 ionized calcium-binding
adaptor molecule
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Hypoxic-ischemic or inflammatory insults in infants
born very prematurely (< 32 weeks of gestation) cause
oligodendrocyte progenitor cells to arrest their matur-
ation which results in white matter injury [49, 50].
Our results implicating an anti-inflammatory func-
tion of hWJ-MSC-derived exosomes are in line with
previous studies documenting the repressive effect of
MSC and their derived extracellular vesicles on
microglial activation. Supporting our observations, it
was recently demonstrated that extracellular vesicles
retrieved from human bone marrow MSC reduced
microgliosis in a rat model of inflammation-induced
preterm brain injury [51]. Moreover, exosomes
derived from exfoliated deciduous teeth stem cells
have also been reported to inhibit IL-6 and TNFα
production in LPS-stimulated BV-2 microglial cells
and to dampen microglia activation in an animal
model of traumatic brain injury [9]. Similar effects
were observed in a transwell co-culture system with
mouse bone marrow MSC and BV-2 cells. Upon LPS
stimulation, the presence of MSC in the co-culture
decreased TNFα expression but increased IL-6
expression in a cell dose-dependent manner [12].
While the decreased TNFα expression is in line with our
study, the increased IL-6 level is not. This discrepancy can
partially be explained by the fact that in the aforemen-
tioned study, the IL-6 was not only produced by BV-2
cells but also by MSC [12]. Interestingly, immunomodula-
tory capacities comparable to the ones of exosomes were
also described for bone marrow MSC-derived microvesi-
cles (MV) [10]. MSC-MV were able to decrease
pro-inflammatory cytokines such as IL-6 and TNFα and
to inhibit the phosphorylation of the MAPK family mole-
cules in the TLR4/CD14 pathway in LPS-stimulated BV-2
cells [10].
Our findings further support studies investigating
the therapeutic potential of MSC-derived exosomes in
preterm-associated diseases. hWJ-MSC-derived exo-
somes have been successfully used to treat broncho-
pulmonary dysplasia [29] and hypoxia-induced
pulmonary hypertension [52] in newborn mice. Simi-
lar to our results, hWJ-MSC-derived exosomes damp-
ened hyperoxia-induced inflammation by decreasing
the transcription of Il6 and Tnf in alveolar macro-
phages [29] and prevented hypoxia-induced macro-
phage infiltration into the lungs [52]. Exosomes
derived from bone marrow MSC have also been
proven to be an effective treatment for necrotizing
enterocolitis as they reduced the incidence and the
extent of the disease in premature newborn rats [28].
Stem cell-based therapies hold great clinical potential
when it comes to treating inflammatory diseases. Stem
cells derived from the tissue of the umbilical cord can be
easily obtained, as umbilical cords are readily available
and otherwise regarded as a biological waste product.
Umbilical cord stem cells can be used as an autologous
graft which substantially reduces the risk of a potential
transplant rejection. Both stem cells [14] and their exo-
somes can be intranasally delivered to the brain and this
non-invasive route of application makes the therapy es-
pecially suitable for translation into clinical practice. Al-
though the intranasal administration of MSC has been
shown to be effective in perinatal brain injury [14], the
use of MSC-derived cell-free vesicles has several add-
itional advantages. For example, it is unavoidable that
upon transplantation into an injured brain, MSC, in con-
trast to MSC-derived exosomes, respond to the inflam-
matory stimuli by producing further pro-inflammatory
molecules [11]. Additionally, MSC have the potential to
get trapped in the lungs [53] and to induce tumor
growth in transplanted tissue [54, 55]. These risks can
be easily eliminated by using MSC-derived exosomes.
Furthermore, exosomes are easier to store compared to
MSC as they can be kept suspended in PBS at − 20 °C.
However, the use of stem cell-derived vesicles as a treat-
ment creates new challenges in terms of their standard-
ized isolation, quantification, characterization, and
storage as well as in terms of their route and timing of
administration [56]. In this study, we administered
hWJ-MSC-derived exosomes at the same time as the in-
jury was introduced. By choosing such an early time
point of treatment, we were able to demonstrate a
strong anti-inflammatory effect of the exosomes in the
acute phase of the injury. Future research will focus on
evaluating the exosomes as a post-injury treatment to in-
crease their clinical relevance. Finding the optimal time
point(s) of administration and dosage are major chal-
lenges in the standardization of vesicle therapies and re-
main to be solved before such treatments will make
their way into the clinics.
Conclusions
In conclusion, hWJ-MSC-derived exosomes have anti-in-
flammatory effects on microglia in perinatal brain injury.
These anti-inflammatory effects are at least in part caused
by exosome-mediated interference with the TLR4/CD14
signaling cascade, thereby leading to a dampened tran-
scription of inflammation-related genes. In the brain, exo-
somes reduce neuroinflammation by suppressing the
transcription and secretion of pro-inflammatory cytokines
and inhibiting the accumulation of microglia. This mech-
anism prevents an exacerbated inflammatory reaction,
which is important to avoid secondary brain injury leading
to subsequent neurological deficits. Hence, hWJ-MSC-de-
rived exosomes represent a promising future cell-free
therapy to prevent and treat perinatal brain injury in pre-
term infants.
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